A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

计划入组 158 人 · 首次发布于 2020 年 9 月 16 日

A Study of TAK-505 in Adults With Solid Tumors

计划入组 151 人 · 首次发布于 2026 年 2 月 27 日

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

计划入组 4 人 · 首次发布于 2013 年 4 月 24 日

AP-505

TP-505

CAT-505

AB&B BIO-TECH-B

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

Arna Pharma and Slate Run Pharmaceuticals Form Joint Venture to Create Scaled U.S. Specialty Pharmaceutical Platform

FDA Approves Multiple ANDAs and 505(b)(2) Applications in Q3

LadRx Plans NDA Submission for Aldoxorubicin Under 505(b)(2) Pathway